These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38833140)

  • 21. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
    van Hartingsveldt B; Nnane IP; Bouman-Thio E; Loza MJ; Piantone A; Davis HM; Petty KJ
    Br J Clin Pharmacol; 2013 May; 75(5):1289-98. PubMed ID: 23043368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects.
    Sheng L; Cao W; Lin P; Chen W; Xu H; Zhong C; Yuan F; Chen H; Li H; Liu C; Yang M; Li X
    Drug Des Devel Ther; 2021; 15():1101-1110. PubMed ID: 33727798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis.
    Nakagawa H; Iizuka H; Nemoto O; Shimabe M; Furukawa Y; Kikuta N; Ootaki K
    J Dermatol Sci; 2020 Aug; 99(2):82-89. PubMed ID: 32651105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.
    Emu B; Luca D; Offutt C; Grogan JL; Rojkovich B; Williams MB; Tang MT; Xiao J; Lee JH; Davis JC
    Arthritis Res Ther; 2012 Jan; 14(1):R6. PubMed ID: 22225620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
    Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
    Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
    Lin D; Xiao H; Yang K; Li J; Ye S; Liu Y; Jing S; Lin Y; Yang Y; Huang L; Yuan J; Li Z; Yang J; Gao H; Xie Y; Xu M; Yan L
    BMC Med; 2024 May; 22(1):209. PubMed ID: 38807146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
    Lim CN; Kantaridis C; Huyghe I; Gorman D; Berasi S; Sonnenberg GE
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00813. PubMed ID: 34369667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.
    Yang Y; Yu L; Sheng Z; Lin H; Weng Z; Song W; Cao B; Zhao Y; Gao Y; Ni S; Wang H; Ma T; Huang L; Sun C; Li J
    Front Pharmacol; 2024; 15():1327008. PubMed ID: 38741586
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
    Yang H; Merica E; Chen Y; Cohen M; Goldwater R; Kosinski PA; Kung C; Yuan ZJ; Silverman L; Goldwasser M; Silver BA; Agresta S; Barbier AJ
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):246-259. PubMed ID: 30091852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.
    Iyengar SR; Hoyte EG; Loza A; Bonaccorso S; Chiang D; Umetsu DT; Nadeau KC
    Int Arch Allergy Immunol; 2013; 162(1):89-93. PubMed ID: 23816920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
    Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
    Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
    Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X
    Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.
    Zhao Y; Zhang J; Yang B; Li J; Ding Y; Wu L; Zhang L; Wang J; Zhu X; Zhang F; Tao X; Li Y; Zhang C; Li L; Lu J; Diao Q; Lu Q; Man X; Li F; Xia X; Cheng H; Jia Y; Zhao G; Yan J; Chen B
    Chin Med J (Engl); 2024 Jan; 137(2):200-208. PubMed ID: 37482623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgE
    Ye YM; Park JW; Kim SH; Cho YS; Lee SY; Lee SY; Sim S; Song E; Kim B; Lee J; Kim SK; Jang MH; Park HS
    Int Immunopharmacol; 2024 Mar; 130():111706. PubMed ID: 38382265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial.
    Zhang Y; Yan B; Zhu Z; Wang X; Song X; Zhu D; Ma T; Zhang Y; Meng C; Wang G; Wang C; Zhang L
    EClinicalMedicine; 2024 Mar; 69():102467. PubMed ID: 38356731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Silverberg JI; Wollenberg A; Reich A; Thaçi D; Legat FJ; Papp KA; Stein Gold L; Bouaziz JD; Pink AE; Carrascosa JM; Rewerska B; Szepietowski JC; Krasowska D; Havlíčková B; Kalowska M; Magnolo N; Pauser S; Nami N; Sauder MB; Jain V; Padlewska K; Cheong SY; Fleuranceau Morel P; Ulianov L; Piketty C;
    Lancet; 2024 Aug; 404(10451):445-460. PubMed ID: 39067461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.